AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

Brain implants, made from small clusters of brain cells, could help restore neural pathways damaged by Parkinson’s disease.

Jan. 21, 2025 — The B vitamin mitigates manganese neurotoxicity, which produces symptoms that resemble Parkinson's disease. The vitamin improves dopamine production in the brain and offers ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...